Sweden · Delayed Price · Currency is SEK Senzime AB Company Description
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.
The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current.
It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo’s intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system.
Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
| Country | Sweden |
| Founded | 1999 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Philip Siberg |
Contact Details
Address: Verkstadsgatan 8 Uppsala, 753 23 Sweden | |
| Phone | 46 18 51 56 40 |
| Website | senzime.com |
Stock Details
| Ticker Symbol | SEZI |
| Exchange | Nasdaq Stockholm |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0002478776 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Philip Siberg | Chief Executive Officer |
| Slavoljub Grujicic | Chief Financial Officer |
| Johanna Tulkki | Executive Vice President and Chief Operating Officer |
| Anders Jacobson | Chief Scientific Officer |
| Paula Treutiger | Head of Communication and Investor Relations |
| Michael Noble | Chief Marketing Officer |
| Catrin Molund | Executive Vice President of Business Development |
| Johanna Faris | Head of Q/RA/S |